Ingenza is delighted to announce its relocation to The Moubray Building at Edinburgh Technopole, part of the Pioneer Group. The new site is still within the Midlothian Science Zone – a world-leading centre of research excellence in life sciences – and is now fully operational, marking a significant milestone in the company’s continued growth.
Ingenza is a technology-driven contract research, development and manufacturing organisation (CRDMO) that specialises in biologics, small molecule pharmaceuticals and sustainably manufactured industrial products. This move follows a strategic review of the company’s long-term development plans, and the bespoke, state-of-the-art, multi-million-pound Moubray Building is designed to more than double Ingenza’s operational footprint. The expansion will significantly increase capacity across all service areas, strengthening the company’s ability to deliver flexible, scalable solutions to its growing customer base. The innovative design will allow Ingenza to scale up manufacturing to 100L, paving the way for the production of first-in-human materials.
Jaymin Amin, Chief Business Officer of Ingenza, commented: “This is a landmark investment for Ingenza. It will enable us to significantly increase our operational scale, further expand our research and development laboratories, and enhance our bespoke service offerings to better support the growth of our customers. Central to this expansion is our inGenius® platform technology, which is revolutionising drug substance development for investigational new drug (IND)-enabling studies. This exciting move is not only about gaining physical space; it will also act as a catalyst to accelerate innovation and reinforce our position as a trusted partner in bioprocess development for complex drug substances.”
Ingenza’s CEO Ian Fotheringham added: “Our increased automation and computational biology capabilities at Moubray will turbocharge the expansion of our data-driven codABLE® gene design. Having already enhanced predictability, development speed and performance of protein production in E.coli and Bacillus spp., we now anticipate that codABLE® machine learning will shave weeks or even months off the timeline for delivery of optimised recombinant Pichia pastoris and CHO manufacturing hosts.”
John Mackenzie, Director for Scotland at Pioneer Group, said: “Ingenza’s growth is hugely positive for our local life sciences cluster. It is an exemplar of the Pioneer model of local economic development and partnership to accelerate scientific discovery.”